On May 15, 2025, velaglucerase beta for injection (CAN103), an innovative therapeutic drug for Gaucher disease developed through Phase I/II clinical trials led by PUMCH, received marketing approval from the National Medical Products Administration (NMPA) of Ch...

Recently, a genomic study on anti-MDA5 antibody-positive dermatomyositis completed through collaboration between the Department of Rheumatology at PUMCH (led by Director Li Mengtao and Deputy Director Wang Qian) and the Second Affiliated Hospital of Nanchang U...

From April 12 to 16, 2025, the China-U.S. Youth Health Academic Visit and the U.S.-China Youth Health Dialogue were held in Fujian and Guangdong provinces. These activities were organized by the Chinese People's Association for Friendship with Foreign Countrie...

Cysteinyl leukotriene receptor 2 (CysLT2R) has recently become a "rising star" in drug development due to its unique tissue distribution and physiological functions. Recently, a collaborative team led by Zhang Shuyang, President of PUMCH, and Luan Xiao...